GYREHIGH SIGNALFINANCIAL10-K

GYRE experienced a dramatic revenue collapse while maintaining profitability, coupled with significant balance sheet strengthening and strategic repositioning toward biopharmaceuticals.

The severe revenue decline suggests major operational disruption or strategic pivot, yet the company maintained strong profitability and cash generation, indicating potential one-time factors or deliberate business model changes. The substantial increase in stockholders' equity and current assets suggests either successful fundraising or asset restructuring that has strengthened the financial foundation during this transition period.

Comparing 2026-03-13 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

GYRE's financials show a stark contrast between collapsed revenue performance and robust balance sheet growth, with revenue falling dramatically while the company surprisingly maintained $9.9M in net income and $11.5M in operating income. The balance sheet strengthened meaningfully across key metrics, with stockholders' equity growing 67.5% to $106.0M, current assets expanding 58% to $102.4M, and total assets reaching $166.1M. This unusual combination of severely declining top-line performance alongside strong profitability and balance sheet expansion suggests either a major business model transition or significant one-time events affecting the revenue stream.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-92.4%
$3.6M$275K

Revenue declined 92.4% — significant demand weakness or market share loss warrants investigation.

Stockholders Equity
Balance Sheet
+67.5%
$63.3M$106.0M

Equity base grew 67.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+58.7%
$19.6M$31.1M

Receivables surged 58.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Assets
Balance Sheet
+58%
$64.8M$102.4M

Current assets grew 58% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-48.6%
$2.3M$1.2M

Capex reduced 48.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+48%
$4.3M$6.3M

Inventory surged 48% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Net Income
P&L
-44.8%
$17.9M$9.9M

Net income declined 44.8% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
+32.5%
$125.4M$166.1M

Asset base grew 32.5% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
-28.9%
$16.2M$11.5M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

R&D Expense
P&L
+13.9%
$12.0M$13.7M

R&D investment increased 13.9% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-17
ADDED
As of March 2, 2026, the number of outstanding shares of the registrant s common stock, par value $0.001 per share, was 96,963,611 , which includes 5,649,604 shares of common stock issued in the name of the registrant to a stock plan administrator of the registrant (see Note 8 Stockholders Equity).
Overview We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases.
We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S.
In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis.
Fibrotic diseases affect large patient populations worldwide and involve complex, multi-stage biological processes driven by multiple molecular pathways.
Given this complexity, therapies that modulate key profibrotic signaling pathways may offer meaningful clinical benefit; however, effective treatment may require targeting mechanisms across different stages of disease progression.
Building on our commercialization experience and infrastructure in the PRC, we have expanded our presence into the United States to advance the clinical development of our innovative pipeline, including F351 (Hydronidone), our lead product candidate for liver fibrosis.
Our strategy is to leverage our established commercial portfolio to support and de-risk the advancement of late-stage product candidates, expand approved products into additional indications, and build a diversified pipeline targeting significant unmet medical needs in fibrosis and related inflammatory diseases.
On March 2, 2026, we entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement ) with Cullgen Inc., a Delaware corporation ( Cullgen ), and Helix Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Gyre ( Merger Sub ), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Cullgen, with Cullgen continuing as a wholly owned subsidiary of Gyre and the surviving corporation of the merger (the Merger ).
The consummation of the Merger is subject to certain closing conditions, including, among other things, (1) approval by the requisite Cullgen stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, and (2) a filing under the HSR Act.
REMOVED
As of March 7, 2025, the number of outstanding shares of the registrant s common stock, par value $0.001 per share, was 93,612,442 , which includes 7,280,230 shares of common stock issued in the name of the registrant to a stock plan administrator of the registrant (see Note 8 Stockholders Equity).
Overview We are a commercial-stage pharmaceutical company with a proven track record of financial success developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis.
Fibrotic diseases represent a large patient population with significant unmet medical needs and involve complex, multi-stage processes with multiple pathways.
While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis.
Our strategy is to build on our success in the development and commercialization of ETUARY (pirfenidone) to expand into new indications and advance our pipeline of innovative drug candidates.
By leveraging clinically validated compounds, our goal is to drive a de-risked pipeline through late-stage clinical development and commercialization to provide effective treatments for patients in the United States and globally.
ETUARY (pirfenidone) Pirfenidone, the first anti-fibrotic drug approved for idiopathic pulmonary fibrosis ( IPF ) in Japan, the European Union ( EU ), the United States, and the PRC, is a small molecule drug that inhibits the synthesis of Tumor Growth Transforming ( TGF )- 1, Tumor Necrosis Factor ( TNF )- , and other fibrosis and inflammation modulators.
We successfully advanced pirfenidone from research and development ( R D ) to commercialization in the PRC for the treatment of IPF.
In addition to IPF, pirfenidone is undergoing one additional Phase 3 trial in the PRC for the treatment of pneumoconiosis ( PD ) and was undergoing two Phase 3 trials in the PRC for the treatment of dermatomyositis-related interstitial lung disease ("DM-ILD") and sclerosis-related interstitial lung disease ("SSc-ILD") to broaden its indications and market.
We are prioritizing the development of our product candidates for other targeted indications and, as a result, have paused our two Phase 3 trials in the PRC for the treatment of DM-ILD and SSc-ILD.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →